The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy?

The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy?   Abstract The development of tirzepatide, a first in class dual glucose dependent insulinotropic polypeptide and glucagon like peptide 1 receptor agonist, represents a potentially transformative advance in the management of type 2 diabetes and obesity. By simultaneously targeting

GLP-1 Agonists for Obesity in Non-Diabetic Patients: Game Changer or Overhyped? A Critical Analysis

GLP-1 Agonists for Obesity in Non-Diabetic Patients: Game Changer or Overhyped? A Critical Analysis Please like and subscribe if you enjoyed this video :-)    Abstract The treatment landscape for managing weight in non-diabetic patients has changed dramatically with the introduction of

The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy?